PCM
Penserra Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $210K | Buy |
402
+393
| +4,367% | +$205K | ﹤0.01% | 643 |
|
|
2025
Q1 | $5K | Sell |
9
-267
| -97% | -$148K | ﹤0.01% | 925 |
|
|
2024
Q4 | $196K | Buy |
276
+267
| +2,967% | +$190K | ﹤0.01% | 747 |
|
|
2024
Q3 | $9K | Hold |
9
| – | – | ﹤0.01% | 897 |
|
|
2024
Q2 | $9K | Hold |
9
| – | – | ﹤0.01% | 938 |
|
|
2024
Q1 | $8K | Sell |
9
-487
| -98% | -$433K | ﹤0.01% | 932 |
|
|
2023
Q4 | $434K | Sell |
496
-138
| -22% | -$121K | 0.01% | 558 |
|
|
2023
Q3 | $520K | Sell |
634
-110
| -15% | -$90.2K | 0.01% | 495 |
|
|
2023
Q2 | $533K | Buy |
744
+688
| +1,229% | +$493K | 0.01% | 503 |
|
|
2023
Q1 | $45K | Hold |
56
| – | – | ﹤0.01% | 860 |
|
|
2022
Q4 | $40K | Sell |
56
-46
| -45% | -$32.9K | ﹤0.01% | 917 |
|
|
2022
Q3 | $70K | Buy |
102
+86
| +538% | +$59K | ﹤0.01% | 776 |
|
|
2022
Q2 | $9K | Sell |
16
-8,466
| -100% | -$4.76M | ﹤0.01% | 1283 |
|
|
2022
Q1 | $5.92M | Buy |
8,482
+4,800
| +130% | +$3.35M | 0.14% | 183 |
|
|
2021
Q4 | $2.33M | Buy |
+3,682
| New | +$2.33M | 0.05% | 343 |
|
|
2020
Q3 | – | Sell |
-1,690
| Closed | -$1.05M | – | 1018 |
|
|
2020
Q2 | $1.05M | Sell |
1,690
-12,442
| -88% | -$7.75M | 0.05% | 254 |
|
|
2020
Q1 | $6.9M | Buy |
+14,132
| New | +$6.9M | 0.47% | 65 |
|
|
2019
Q1 | – | Sell |
-8,948
| Closed | -$3.34M | – | 786 |
|
|
2018
Q4 | $3.34M | Buy |
+8,948
| New | +$3.34M | 0.32% | 83 |
|
|
2017
Q3 | – | Sell |
-867
| Closed | -$425K | – | 590 |
|
|
2017
Q2 | $425K | Buy |
+867
| New | +$425K | 0.15% | 112 |
|
|
2017
Q1 | – | Sell |
-49
| Closed | -$17K | – | 779 |
|
|
2016
Q4 | $17K | Buy |
49
+8
| +20% | +$2.78K | ﹤0.01% | 704 |
|
|
2016
Q3 | $16K | Buy |
41
+16
| +64% | +$6.24K | ﹤0.01% | 681 |
|
|
2016
Q2 | $9K | Buy |
25
+10
| +67% | +$3.6K | ﹤0.01% | 749 |
|
|
2016
Q1 | $5 | Sell |
15
-1,163
| -99% | -$388 | ﹤0.01% | 849 |
|
|
2015
Q4 | $639K | Buy |
+1,178
| New | +$639K | 0.06% | 111 |
|